Search research articles
Contact Us
Filters
Showing results (401-410 of 499) with videos related to
Page
of 50
Sort By:
Lancet (London, England)
|
April 17, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Kohei Shitara, Florian Lordick, Yung-Jue Bang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2023
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Dung T Le, Luis A Diaz, Tae Won Kim, et al.
Lancet (London, England)
|
October 23, 2023
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Yelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, et al.
The Lancet. Oncology
|
March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
Marc Peeters, Timothy Jay Price, Andrés Cervantes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2009
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
James C Yao, Catherine Lombard-Bohas, Eric Baudin, et al.
Cancer Chemotherapy and Pharmacology
|
July 27, 2017
Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial
Allen Lee Cohn, Takayuki Yoshino, Volker Heinemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Hani M Babiker, Vincent Picozzi, Sreenivasa R Chandana, et al.
Journal of the National Cancer Institute
|
October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis
Xavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
Page
of 50
Search research articles
Search
Showing results (401-410 of 499) with videos related to
Sort By:
Page
of 50
Lancet (London, England)
|
April 17, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Kohei Shitara, Florian Lordick, Yung-Jue Bang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2023
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Dung T Le, Luis A Diaz, Tae Won Kim, et al.
Lancet (London, England)
|
October 23, 2023
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Yelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, et al.
The Lancet. Oncology
|
March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
Marc Peeters, Timothy Jay Price, Andrés Cervantes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2009
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
James C Yao, Catherine Lombard-Bohas, Eric Baudin, et al.
Cancer Chemotherapy and Pharmacology
|
July 27, 2017
Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial
Allen Lee Cohn, Takayuki Yoshino, Volker Heinemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Hani M Babiker, Vincent Picozzi, Sreenivasa R Chandana, et al.
Journal of the National Cancer Institute
|
October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis
Xavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
Page
of 50